05 Sep Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, ainsi que al
147. Brentuximab vedotin or healthcare provider's alternatives inside the CD30-self-confident cutaneous T-telephone lymphoma (ALCANZA): a global, open-identity, randomised, stage step 3, multicentre trial. Lancet (2017) –66. doi: /S0140-6736(17)31266-7
148. DeFilipp Z, Li S, Kempner Me, Brownish J, Del Rio C, Valles B, ainsi que al. Phase I Demonstration from Brentuximab Vedotin for Steroid-Refractory Persistent Graft-versus-Servers State once Allogeneic Hematopoietic Telephone Transplantation. doi: /j.bbmt.
149. Alexander KA, Flynn Roentgen, Lineburg KE, Kuns RD, Teal End up being, Olver SD, mais aussi al. CSF-1-dependent donor-derived macrophages mediate persistent graft-versus-machine situation.